A Potentially Underestimated Predictor of Coronary Artery Disease Risk: The ApoB/ApoA1 Ratio

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jun 14

PMID 38873661

Authors

Bo Li

Xu Zhao

Yan Ding

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease (CVD) is the leading cause of death worldwide, and statin therapy is the cornerstone of atherosclerotic cardiovascular disease. However, clinical practice is unsatisfactory, and there is significant interest in the risk of residual cardiovascular events. Traditional study methods make it difficult to exclude the crosstalk of confounding factors, and we investigated the impact of the ApoB/ApoA1 ratio on CVD using two-sample Mendelian randomization (MR) and multivariate Mendelian randomization (MVMR) methods.

Methods: Two-sample MR and MVMR analyses were performed using pooled statistics from genome-wide association studies (GWAS) of ApoB/ApoA1 ratio (BAR), lipoprotein (a) (Lp(a)), and triglyceride (TG) in Europeans to assess the causal relationship between BAR, Lp(a), and TG with coronary artery disease (CAD).

Results: The genetic prediction of BAR was significantly correlated with CAD (Inverse variance weighted (IVW) beta = 0.255; OR = 1.291; 95 % CI = 1.061-1.571; P = 0.011) in a two-sample MR analysis. MVMR studies showed that BAR (beta = 0.373; OR = 1.452; 95 % CI = 1.305-1.615; P = 7.217e-12), Lp (a) (beta = 0.238; OR = 1.269; 95 % CI = 1.216-1.323; P = 2.990e-28), and TG (beta = 0.155; OR = 1.168; 95 % CI = 1.074-1.270; P = 2.829e-04) were significantly associated with CAD. After further colinearity analyses of LASSO regressions, the results of multivariate analyses were similar for IVW, MR-Egger, MR-Lasso, and median methods.

Conclusion: BAR is causally related to coronary artery disease. BAR is an independent predictor of CAD risk, independent of routine lipid measurements and other risk factors. TG and Lp(a) may be causally related to CAD, subject to verification in clinical practice.

References

Clarke R, Von Ende A, Schmidt L, Yin X, Hill M, Hughes A . Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease. Circ Res. 2023; 132(4):452-464. PMC: 9930889. DOI: 10.1161/CIRCRESAHA.122.321690. View

Chazov E, Tertov V, Orekhov A, Lyakishev A, Perova N, Kurdanov K . Atherogenicity of blood serum from patients with coronary heart disease. Lancet. 1986; 2(8507):595-8. DOI: 10.1016/s0140-6736(86)92426-8. View

Cromwell W, Otvos J, Keyes M, Pencina M, Sullivan L, Vasan R . LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol. 2009; 1(6):583-92. PMC: 2720529. DOI: 10.1016/j.jacl.2007.10.001. View

Walldius G, de Faire U, Alfredsson L, Leander K, Westerholm P, Malmstrom H . Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: A cohort study. PLoS Med. 2021; 18(12):e1003853. PMC: 8635349. DOI: 10.1371/journal.pmed.1003853. View

Ibi D, Blauw L, Noordam R, Dolle M, Jukema J, Rosendaal F . Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles are associated with an additively improved lipoprotein profile. Atherosclerosis. 2021; 328:144-152. DOI: 10.1016/j.atherosclerosis.2021.04.015. View

Larsson S, Butterworth A, Burgess S . Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J. 2023; 44(47):4913-4924. PMC: 10719501. DOI: 10.1093/eurheartj/ehad736. View

Al Hageh C, Chacar S, Ghassibe-Sabbagh M, Platt D, Henschel A, Hamdan H . Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions. Vasc Health Risk Manag. 2023; 19:31-41. PMC: 9871050. DOI: 10.2147/VHRM.S394134. View

Catapano A, Graham I, De Backer G, Wiklund O, Chapman M, Drexel H . 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39):2999-3058. DOI: 10.1093/eurheartj/ehw272. View

ODonnell M, McQueen M, Sniderman A, Pare G, Wang X, Hankey G . Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE). J Stroke. 2022; 24(2):224-235. PMC: 9194539. DOI: 10.5853/jos.2021.02152. View

10.

Walldius G, Jungner I, Holme I, Aastveit A, Kolar W, Steiner E . High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2002; 358(9298):2026-33. DOI: 10.1016/S0140-6736(01)07098-2. View

11.

Lamprea-Montealegre J, Sharrett A, Matsushita K, Selvin E, Szklo M, Astor B . Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study. Atherosclerosis. 2014; 234(1):42-6. DOI: 10.1016/j.atherosclerosis.2014.02.006. View

12.

Varbo A, Benn M, Nordestgaard B . Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2013; 141(3):358-67. DOI: 10.1016/j.pharmthera.2013.11.008. View

13.

Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

14.

Holme I, Cater N, Faergeman O, Kastelein J, Olsson A, Tikkanen M . Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Ann Med. 2009; 40(6):456-64. DOI: 10.1080/07853890801964955. View

15.

Guo X, Zhai Y, Song C, Mi Z, Peng J, Guo J . Elevated postprandial triglyceride-rich lipoproteins in patients with diabetes and stable coronary artery disease correlated with early renal damage and systemic inflammation. Lipids Health Dis. 2023; 22(1):58. PMC: 10158000. DOI: 10.1186/s12944-023-01820-4. View

16.

Burgess S, Butterworth A, Thompson S . Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658-65. PMC: 4377079. DOI: 10.1002/gepi.21758. View

17.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

18.

Sarwar N, Sandhu M, Ricketts S, Butterworth A, Di Angelantonio E, Boekholdt S . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375(9726):1634-9. PMC: 2867029. DOI: 10.1016/S0140-6736(10)60545-4. View

19.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

20.

Gilliland T, Liu Y, Mohebi R, Miksenas H, Haidermota S, Wong M . Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. J Am Coll Cardiol. 2023; 81(18):1780-1792. PMC: 10824318. DOI: 10.1016/j.jacc.2023.02.050. View